Please try another search
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Name | Age | Since | Title |
|---|---|---|---|
| Mark Schubert | - | - | Member of Oral Mucositis Medical Advisory Board |
| James Markowitz | - | - | Member of Pediatric Crohn's Disease Medical Advisory Board |
| Gary Wood | - | - | Member of Cutaneous T-Cell Lymphoma Medical Advisory Board |
| Christopher J. Schaber | 58 | 2006 | Chairman of the Board of Directors, CEO & President |
| W. Joost Wiersinga | - | - | Member of Melioidosis Scientific Advisory Board |
| Gregory Anthony Lapointe | 65 | 2009 | Independent Director |
| Alain H. Rook | - | - | Member of Cutaneous T-Cell Lymphoma Medical Advisory Board |
| Jeffrey Hyams | - | - | Member of Pediatric Crohn's Disease Medical Advisory Board |
| Joel Rosh | - | - | Member of Pediatric Crohn's Disease Medical Advisory Board |
| Bart Currie | - | - | Member of Melioidosis Scientific Advisory Board |
| Yusuf Yazici | - | 2024 | Member of Behcet's Disease Medical Advisory Board |
| Direk Limmathurotsakul | - | - | Member of Melioidosis Scientific Advisory Board |
| Andrew Sulich | - | 2024 | Member of Behcet's Disease Medical Advisory Board |
| Robert J. Rubin | 78 | 2009 | Independent Director |
| Dorothy Mary Kate Keefe | - | - | Member of Oral Mucositis Medical Advisory Board |
| Jerome Bernard Zeldis | 74 | 2011 | Independent Director |
| Youn Kim | - | - | Member of Cutaneous T-Cell Lymphoma Medical Advisory Board |
| Madeleine Duvic | - | - | Member of Cutaneous T-Cell Lymphoma Medical Advisory Board |
| David AB Dance | - | - | Member of Melioidosis Scientific Advisory Board |
| Diane L. Parks | 72 | 2019 | Independent Director |
| Johannes Nowatzky | - | 2024 | Member of Behcet's Disease Medical Advisory Board |
| Gülen Hatemi | - | 2024 | Member of Behcet's Disease Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
